EUVIMEDEUVIMED entdecken
Crossref

Extracellular Vesicle Biomarkers in Systemic Lupus Erythematosus and Lupus Nephritis: Emerging Roles in Pathogenesis, Biomarker Development, and Clinical Translation

Aarti Verma¹, Vineeta Batra, Jayanand None

Biomedicine · 25.09.2026 · 46 (3) · 171-182

DOI: 10.51248/v46i3.82 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomedicine, online erschienen am 25.09.2026. Verfasst von Aarti Verma¹ und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease characterized by loss of immune tolerance, autoantibody production, immune-complex deposition, and persistent inflammation. Lupus nephritis (LN) is a serious manifestation of SLE, affecting approximately 4060 of patients and contributing substantially to morbidity and mortality. Conventional biomarkers, including anti-double-stranded DNA antibodies, complement C3C4, proteinuria, and serum creatinine, incompletely reflect molecular disease activity, while renal biopsy, although the gold standard, is invasive and unsuitable for frequent longitudinal assessment. Extracellular vesicles (EVs) are membrane-enclosed particles that can transport proteins, lipids, messenger RNAs, microRNAs (miRNAs), long non-coding RNAs (lncRNAs), circular RNAs (circRNAs) and DNA. Their cargo reflects the state of parent cells and participates in immune activation, type I interferon signaling, complement dysregulation, endothelial injury, and renal inflammation. This review synthesizes evidence on EV biology and immunopathogenesis in SLELN and critically evaluates EV-associated proteins, miRNAs, and emerging non-coding RNAs as biomarkers. Proteomic and multi-omics approaches increasingly support multi-analyte signatures rather than single biomarkers. Major barriers to translation include heterogeneous isolation methods, incomplete vesicle characterization, small cohorts, variable analytical workflows, limited external validation, and lack of standardized normalization. Future clinical utility will depend on MISEV-aligned workflows, prospective multicentre validation, comparison with established biomarkers, and integration of EV-associated molecular profiles with clinical data and artificial intelligence. EVs therefore represent a promising liquid-biopsy platform, but clinical adoption requires rigorous standardization and demonstration of incremental value over existing tools.

Zitieren

APA

Verma¹, A., Batra, V., & None, J. (2026). Extracellular Vesicle Biomarkers in Systemic Lupus Erythematosus and Lupus Nephritis: Emerging Roles in Pathogenesis, Biomarker Development, and Clinical Translation. Biomedicine, 46(3), 171-182. https://doi.org/10.51248/v46i3.82

Vancouver

Verma¹ A, Batra V, None J. Extracellular Vesicle Biomarkers in Systemic Lupus Erythematosus and Lupus Nephritis: Emerging Roles in Pathogenesis, Biomarker Development, and Clinical Translation. Biomedicine. 2026;46(3):171-182. doi:10.51248/v46i3.82

BibTeX
@article{Verma2026,
  author = {Verma¹, Aarti and Batra, Vineeta and None, Jayanand},
  title = {Extracellular Vesicle Biomarkers in Systemic Lupus Erythematosus and Lupus Nephritis: Emerging Roles in Pathogenesis, Biomarker Development, and Clinical Translation},
  journal = {Biomedicine},
  year = {2026},
  volume = {46},
  number = {3},
  pages = {171--182},
  doi = {10.51248/v46i3.82}
}
Kostenlos starten →